Nonalcoholic Steatohepatitis

Nonalcoholic steatohepatitis (NASH) has no cure, and the disease is highly underdiagnosed. Prevalence is expected to rise in the coming years, so the need for treatments is high.

NASH clinical trials have notoriously high screening failure rates. Our clinical research experience and proprietary site networks enable us to implement innovative NASH study design and execution tactics that fine-tune recruitment procedures, accelerate study startup, and shorten project timelines.

Meet our leaders for NASH clinical trials

Our scientific leader for NASH is Prof. dr. Manuel Castro Cabezas, a Julius Clinical scientific officer and senior consultant for internal medicine, endocrinology, and vascular medicine at the Franciscus Gasthuis Rotterdam. He has also been at the forefront of creating the NASH Think Tank, a group of leading NASH experts who meet regularly to refine best practices.

Meet our leaders for NASH clinical trials

Julius Clinical is also proud to work with Prof. dr. Christophe Moreno, professor in gastroenterology and hepatology, clinical director of the liver unit at CUB Hôpital Erasme, Brussels, Belgium, and consultant to the NASH Clinical team.

Our proprietary network, NASH Clinical, is a global network of clinicians and investigators that includes endocrinologists, gastroenterologists, diabetologists, and general internists with connections to hospitals worldwide. They have vast experience as a group and are devoted to improving NASH trials.

Read more

The leading NASH experts of the Think Tank meet on a regular basis to discuss the current state of the field and innovative approaches for NASH studies. Under Dr. Castro Cabezas’ leadership, they work to increase understanding of NAFLD and NASH, create expert centres for NASH clinical trials, and help provide better patient recruitment and retention rates for NASH Sponsors.

Prof. Manuel Castro Cabezas​, MD.

Chair and Scientific Officer at Julius Clinical

Prof. Dr. Christophe Moreno, MD.

Scientific board member

Prof. Dr. Diederick E. Grobbee, MD.

Board member and CSO at Julius Clinical

Prof. Maarten E. Tushuizen

Leidsch Universitair Medisch Centrum

Prof. Sven Francque

Antwerp University Hospital

Prof. Onno Holleboom

Amsterdam UMC

Prof. Jörn Schattenberg

University Medical Center Mainz

Prof. Helena Cortez-Pinto

Prof. Lawrence Serfaty

Hôpital Hautepierre Hôpitaux Universitaires Strasbourg

Prof. Manuel Romero Gomez

University of Seville

Prof. Marja Ritta Taskinen

Helsinki University Central Hospital

To help in the early identification of NASH patients, Julius Clinical initiated the Global Research Initiative for Patients screening on NASH (GRIP on NASH) research project. This is a multinational program in which at-risk patients are screened for NAFLD and NASH. Through GRIP on NASH, the number of patients per site per year could be doubled or even tripled, greatly alleviating the difficulty of a depleted NASH patient population.

We are dedicated to providing fast, high-quality patient recruitment and retention rates for NASH clinical trials, Our team has years of experience and will provide a tailor-made solution that suits your trial’s exact needs.

Our expert NASH team

Julius Clinical has an expert team that can conduct streamlined global NASH clinical trials. This in-house team brings insightful solutions to the biggest challenges, including scarcity of qualified sites and adequate access to patients.

Martin czakon
Rick grobbee
Marcel bootsma
Marco alings
Vivian de jong
Elizabeth liano callahan

Related webinars

  • Webinars
  • Cardio-Metabolic Diseases, NASH
  • 23-05-2023

Upcoming webinar: Why NASH trials frequently fail and how to improve them

The upcoming NASH clinical webinar promises to be an insightful and informative session, with our scientific officer Manuel Castro Cabezas as the guest speaker. Manuel will be sharing his expertise on the topic of "Why NASH trials frequently fa...

Speakers: Prof. Manuel Castro Cabezas - Prof. dr. Christophe Moreno, M.D.

NAFLD: patient identification strategies

In this webinar, Prof. Jörn Schattenberg discussed his paper in Nature Reviews Gastroenterology & Hepatology on effective and efficient models of care for patients with NAFLD. Standardized patient care pathways for NAFLD are not yet widely im...

Speakers: Prof. Manuel Castro Cabezas - Prof. dr. Christophe Moreno, M.D.

NASH resources

Explore our NASH capabilities, case studies, and other resources.


"*" indicates required fields

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Request for proposal

"*" indicates required fields

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
This field is for validation purposes and should be left unchanged.


Twitter Facebook LinkedIn